[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gist---gastrointestinal-stromal-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gist---gastrointestinal-stromal-tumor":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,70,97,131,157,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100054129","lrg-gist-patient-registry-100054129",false,"NCT07697248","LRG GIST Patient Registry","Life Raft Group GIST Registry Protocol","Inclusion Criteria:\n\n1. Gastrointestinal Stromal Tumor diagnosis\n2. Provide written and informed consent\n\nExclusion Criteria:\n\n\\-","ALL",{"count":18,"type":19},5000,"ESTIMATED","25 Years","OBSERVATIONAL","The Life Raft Group (LRG) Patient Registry is a structured database that collects comprehensive information about individuals diagnosed with GIST. The purpose of this registry is to facilitate research, improve understanding of the disease, track patient outcomes, and ultimately enhance patient care.",[24,25,26],"GIST","GIST - Gastrointestinal Stromal Tumor","Gastrointestinal Stromal Tumor (GIST)",[24],"RECRUITING","2026-07-08",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2013-04",{"date":36,"type":19},"2099-12-31",{"name":38,"class":39},"The Life Raft Group","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100622086","phase-2-efficacy-and-safety-of-nb003-in-patients-with-advanced-gastrointestinal-stromal-tumors-gist-100622086","NCT07379047","Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","GISTAR-1","Inclusion Criteria:\n\n1. Participants are \\>=18 years of age (or the legal adult age as per local regulations, whichever is older) at the time of signing the ICF.\n2. Participants, or legally authorized representatives permitted by local regulations, provide written informed consent for participation in the study.\n3. Participants who have histologically confirmed locally advanced, unresectable, or metastatic GIST.\n\n   1. Part 1: Patients who have failed prior treatment with imatinib (including adjuvant therapy) and sunitinib for GIST due to disease progression or intolerance. Participants should also have no prior use of other TKI drugs.\n   2. Part 2: Patients who have failed prior treatment with imatinib (including adjuvant therapy) for GIST due to disease progression or intolerance. Participants should also have no prior use of other TKI drugs.\n4. Participants with confirmed KIT gene mutation based on local or central laboratory molecular pathology reports. Mutation status must be determined using tissue-based PCR or DNA sequencing methods. The report should include results on the presence or absence of KIT exon 9\u002F11\u002F17 mutations for randomization stratification in Part 1 and efficacy-related analyses throughout the study. The molecular pathology report indicating KIT mutation status shall be submitted to the medical monitor for review during the screening period. If a local molecular pathology report is unavailable or provides insufficient information, archived tumor tissue samples or fresh biopsy samples must be provided for central laboratory confirmation of mutation status prior to enrollment.\n5. Participants with at least one measurable lesion according to mRECIST.\n6. Participants with an ECOG PS of 0 to 1.\n7. Tumor sample requirement: Archival tumor samples in the form of formalin-fixed paraffin-embedded (FFPE) tissue sections or FFPE blocks obtained prior to enrollment, or tissue samples from a tumor biopsy (excisional, core needle, or fine-needle aspiration).\n8. Participants with an expected life expectancy of \\>=12 weeks.\n9. Participants shall have adequate organ and bone marrow function. Transfusions and\u002For treatment with erythropoietin and\u002For granulocyte colony stimulating factor\u002Fgranulocyte macrophage colony stimulating factor (G-CSF\u002FGM-CSF) are not permitted within 14 days prior to the screening laboratory blood draw under any circumstances. The criteria are defined as follows:\n\n   * Hemoglobin \\>=9 g\u002FdL (5.59 mmol\u002FL).\n   * Absolute neutrophil count (ANC) \\>=1.5 x 10\\^9\u002FL (1500\u002Fmm\\^3).\n   * Platelet count \\>=100 x 10\\^9\u002FL (100,000\u002Fmm\\^3).\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C= 2.5 x upper limit of normal (ULN) (for participants without liver metastases); AST and ALT \\\u003C= 5 x ULN (for participants with liver metastases).\n   * Total bilirubin \\\u003C=1.5 x ULN. Participants with a confirmed diagnosis of Gilbert's syndrome (persistent or recurrent unconjugated hyperbilirubinemia in the absence of hemolysis or hepatic pathology) may be enrolled if total bilirubin \\\u003C=3 x ULN.\n   * Creatinine clearance \\>=60 mL\u002Fmin as calculated by the Cockcroft-Gault formula or 24-hour urine collection.\n   * International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) \\\u003C=1.5 x ULN; however, if a participant is receiving anticoagulant therapy, PT or aPTT within the therapeutic range of the anticoagulant is acceptable.\n10. Male participants: Male participants must agree to use contraception as detailed in Appendix 9 during the treatment period and for at least 6 months after the last dose of study treatment and refrain from donating sperm during this period.\n11. Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n    i) She is not a woman of childbearing potential (WOCBP) as defined in the Appendix 9; or ii) She is a WOCBP and agrees to follow the contraceptive guidance outlined in the Appendix 9 during the treatment period and for at least 6 months after the last dose of study treatment.\n12. WOCBP must have a negative serum pregnancy test result during screening within 14 days prior to enrollment.\n\nExclusion Criteria:\n\n1. Part 1: Participants who have received prior treatment with NB003 or regorafenib. Part 2: Participants who have received prior treatment with NB003 or sunitinib.\n2. Participants who have received any systemic anti-tumor therapy within 7 days prior to enrollment.\n3. Participants who have undergone major surgery (excluding vascular access placement, tumor biopsy, and feeding tube placement) or major palliative interventions (such as transarterial chemoembolization) within 4 weeks prior to enrollment.\n4. Participants who have received radiation therapy to \\>30% of the bone marrow or extensive radiation therapy within 4 weeks prior to enrollment.\n5. Active infection, including active hepatitis B \\[defined as detectable HBV-DNA by local laboratory. Participants who are HBsAg positive or HBcAb positive at screening should have HBV-DNA tested\\] and active hepatitis C \\[defined as detectable HCV-RNA by local laboratory. Participants who are HCV antibody positive at screening should have HCV-RNA tested\\].\n6. Any of the following cardiac-related criteria:\n\n   * Uncontrolled persistent (\\>4 weeks) hypertension (\\>140\u002F90 mmHg).\n   * New York Heart Association (NYHA) Class (Appendix 11) III and IV heart disease, active ischemia, or other uncontrolled cardiac conditions such as angina.\n   * QTc interval Corrected QT interval using Fridericia's formula (QTcF) \\>=470 ms (based on 3 ECG results) or history of long QT syndrome.\n   * Resting ECG showing any clinically significant abnormalities in rhythm, conduction, or morphology (e.g., complete left bundle branch block, atrioventricular block third degree, atrioventricular block second degree, PR interval \\>250 ms).\n   * Left ventricular ejection fraction (LVEF) \\\u003C50%.\n7. Any unresolved prior treatment toxicity greater than CTCAE Grade 1 at the start of study treatment, with the exception of alopecia, hemoglobin (see Inclusion Criterion #10), Grade 2 hypothyroidism stable on hormone replacement therapy, and Grade 2 pre-existing treatment-related neuropathy.\n8. Participants who have experienced a National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 Grade 3 or higher bleeding event within 4 weeks prior to enrollment.\n9. Participants who have experienced an arterial thrombotic or embolic event (e.g., cerebrovascular accident, including transient ischemic attack) within 6 months prior to enrollment, or a venous thrombotic event (including pulmonary embolism or deep vein thrombosis) within 3 months prior to enrollment.\n10. Participants who have experienced a seizure for any reason within 6 months prior to enrollment.\n11. Participants with known bleeding disorders or risk of intracranial hemorrhage (e.g., unexcised or unrepaired cerebral aneurysm, cerebrovascular malformation), or history of intracranial hemorrhage within 1 year prior to randomization.\n12. Participants with unhealed wounds, active ulceration, gastrointestinal perforation, or fracture within 3 months prior to enrollment.\n13. Participants with brain metastases.\n14. History of pancreatitis with prior tyrosine kinase inhibitors use, or current evidence of mild to moderate pancreatitis.\n15. Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulation, or significant bowel resection that may affect adequate absorption of NB003 and regorafenib.\n16. Any other clinically significant comorbidity, such as uncontrolled lung disorder, active infection, uncontrolled pericardial effusion, uncontrolled pleural effusion, or any other condition that, in the investigator's judgment, may affect protocol compliance, interfere with interpretation of study results, or increase participant safety risk.\n17. Participants judged by the investigator to be unwilling or unable (including incompetence) to comply with study procedures, restrictions, and requirements.\n18. Participants currently using (or unable to discontinue at least 2 weeks prior to enrollment) drugs or herbal supplements known to be strong inhibitors or inducers of CYP3A4, and other prohibited concomitant medications (Appendix 3).\n19. History of hypersensitivity to the active or inactive ingredients of NB003, regorafenib, or drugs with similar chemical structure or class to NB003 or regorafenib.\n20. History of other primary neoplasm malignant diagnosed or requiring treatment within 3 years prior to enrollment. The following prior malignancies are not exclusion criteria: completely resected basal cell and squamous cell skin cancers, cured localized prostate cancer, cured superficial or non-muscle invasive bladder cancer, and completely resected carcinoma in situ of any site.","18 Years",{"count":51,"type":19},255,"INTERVENTIONAL",[54,55],"PHASE2","PHASE3","NB003-04 is a phase II\u002FIII, multicenter, open-label clinical study designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of NB003 in patients with gastrointestinal stromal tumors aged 18 years and above (or the legal adult age of consent per local regulations, whichever is older). Participants who are eligible for this study are those who have experienced disease progression or documented intolerance following treatment with either imatinib and sunitinib or following treatment with imatinib.\n\nThis study consists of two parts. Part 1 (hereinafter referred to as Part 1) compares the efficacy of NB003 versus regorafenib in patients who need a third-line therapy for GIST who have failed sequential therapy with imatinib and sunitinib. Part 2 (hereinafter referred to as Part 2) evaluates the efficacy of NB003 in patients who need a second-line therapy for GIST who have failed treatment with imatinib.",[25,58],"Advanced","2026-06-08",{"date":61,"type":32},"2026-06-10",{"date":63,"type":32},"2026-05-11",{"date":65,"type":19},"2028-09-01",{"name":67,"class":68},"Ningbo Newbay Technology Development Co., Ltd","INDUSTRY",32,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":52,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":40},"100640767","a-novel-two-tooth-clip-for-esd-and-eftr-of-gist-100640767","NCT07581977","A Novel Two-Tooth Clip for ESD and EFTR of GIST","Efficacy and Safety of a Novel Two-Tooth Clip-Assisted ESD and EFTR of GIST: A Single-Center, Prospective, Open-Label, Randomized Controlled Study","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 85 years.\n* Patients diagnosed with gastric gastrointestinal lesions clinically indicated for ESD or EFTR.\n* Lesion size between 2 cm and 5 cm in diameter.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Lesions with clear evidence of deep submucosal invasion or distant metastasis precluding curative endoscopic resection.\n* Severe coagulation dysfunction (international normalized ratio \\>2.0, platelet count \\\u003C50,000\u002FµL) or ongoing use of dual antiplatelet therapy\u002Fanticoagulants that cannot be appropriately bridged or discontinued per guidelines.\n* Severe organ failure (cardiac, renal, hepatic, or respiratory) rendering the patient unsuitable for prolonged sedation or general anesthesia.\n* Pregnancy or lactation.\n* Prior surgical or endoscopic intervention at the target lesion site that results in significant fibrosis.","85 Years",{"count":79,"type":19},60,[81],"NA","This study is designed to evaluate the efficacy and safety of a novel two-tooth endoscopic clip, utilized in a \"clip with line\" traction configuration, during endoscopic resection procedures (ESD and EFTR) of GIST. The novel clip's dual-tooth design is intended to provide a more secure anchor on the lesion, enabling effective counter-traction when combined with a line. The primary aim is to determine if this method improves submucosal dissection efficiency compared to conventional ESD. A secondary aim is to evaluate the performance of the same clip system for full-thickness or mucosal defect closure.",[25],[24,85,86,87],"ESD","EFTR","two-tooth clips","2026-05-20",{"date":90,"type":32},"2026-05-22",{"date":92,"type":32},"2026-04-24",{"date":94,"type":19},"2027-07-01",{"name":96,"class":39},"Affiliated Hospital to Academy of Military Medical Sciences",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":52,"phases":106,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100624207","phase-2-kqb198-in-combination-with-imatinib-in-participants-with-advancedmetastatic-gist-in-1st-line-setting-100624207","NCT07406633","KQB198 in Combination With Imatinib in Participants With Advanced\u002FMetastatic GIST in 1st Line Setting","A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced\u002FMetastatic GI Stromal Tumor in 1st Line Setting","Inclusion Criteria\n\nAll Participants:\n\n* Unresectable or metastatic disease\n* Tissue confirmation of GIST\n* Valid results from local testing of blood or tumor tissue documenting the presence of a KIT mutation (must not have exon 9 mutation) or PDGFRA mutation (must not have PDGFRA D842V).\n* Measurable disease per RECIST v1.1.\n* Patients must be in 1st line of treatment for advanced or metastatic disease. Prior imatinib is allowed in adjuvant or neoadjuvant setting, as long as imatinib was stopped over 1 year ago.\n* Adequate organ function and performance status\n\nExclusion Criteria\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Unable to swallow or GI condition that prevents absorption.\n* Other active malignancies within the last 2 years.\n* History of hypersensitivity to any component of KQB198 or imatinib.",{"count":105,"type":19},46,[54],"This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.",[25,24,109,110,111],"GIST Metastatic Cancer","Gastro Intestinal Stromal Tumour","Gastrointestinal Tumors",[113,114,115,116,117,118,119,120],"KQB198","imatinib","gleevec","gist","gastrointestinal stromal tumor","gastro intestinal stromal tumor","gist first line","gist 1st line","2026-05-18",{"date":123,"type":32},"2026-05-19",{"date":125,"type":19},"2026-05",{"date":127,"type":19},"2028-10",{"name":129,"class":68},"Kumquat Biosciences Inc.",8,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":52,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":40},"100635990","phase-2-comparing-regorafenib-combined-with-envafolimab-to-physicians-choice-in-patients-with-metastatic-gastrointestinal-stromal-tumors-harboring-kit-exon-17-mutations-refractory-to-standard-treatment-100635990","NCT07559864","Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment","A Phase II, Open-label, Multicenter, Randomized Controlled Clinical Trial Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment","Inclusion Criteria:\n\n* Aged ≥ 18 years, regardless of gender;\n* Confirmed as gastrointestinal stromal tumor by histopathological examination;\n* Having at least one measurable target lesion meeting the criteria of mRECIST v1.1 (non-lymph node lesions with a long axis ≥ 1.0 cm or a long axis ≥ the thickness of 2 slides); imaging assessment should be performed within 14 days before the first medication;\n* Disease progression or intolerance after treatment with imatinib, sunitinib, regorafenib, or ripretinib;\n* Primary or secondary KIT exon 17 mutation detected by genetic testing;\n* Sufficient organ and bone marrow function, defined as follows: Blood routine: Absolute neutrophil count (ANC) ≥ 1.5×10⁹\u002FL; platelet count (PLT) ≥ 75×10⁹\u002FL; hemoglobin (HGB) ≥ 9.0 g\u002FdL. No use of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), red blood cell transfusion, or platelet transfusion within 14 days before the examination; Liver and kidney function: For subjects without liver metastasis, serum total bilirubin (TBIL) ≤ 1.5×upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN. For subjects with liver metastasis: TBIL ≤ 1.5×ULN; ALT and AST ≤ 5×ULN. Renal function: Serum creatinine (Scr) ≤ 1.5×ULN; Sufficient coagulation function, defined as international normalized ratio (INR) ≤ 1.5 or prothrombin time (PT) ≤ 1.5×ULN; if the subject is receiving anticoagulant therapy, it is acceptable as long as PT is within the range specified for the anticoagulant drug;\n* Provide 15 paraffin-embedded tissue sections before enrollment for immune microenvironment detection;\n* ECOG PS score of 0-2;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* A history of intolerance to regorafenib treatment, or previous receipt of immune checkpoint inhibitor therapy;\n* Being in pregnancy or lactation;\n* Those with an expected survival period of less than 3 months;\n* Those who have undergone major surgery or suffered significant trauma within 4 weeks before the first blood collection during the screening period, or are expected to require major surgery during the study period;\n* Patients with current active ulcers or gastrointestinal bleeding;\n* A history of interstitial lung disease or non-infectious pneumonia; a history of active tuberculosis;\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;\n* Patients with clinically confirmed autoimmune diseases; those with positive HIV or HCV; those with HBV-DNA exceeding the laboratory normal range; those with acute CMV infection;\n* Patients with clinically confirmed central nervous system metastases;\n* Patients with other malignant tumors within 5 years;\n* Immunosuppressed subjects, including those with known immunodeficiency; those currently receiving systemic steroid medications (except those who have used inhaled steroids recently or currently);\n* Uncontrolled hypertension: After active antihypertensive treatment, three consecutive blood pressure measurements indicate systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥ 100 mmHg;\n* Subjects who, in the investigator's assessment, are unable or unwilling to comply with the requirements of the study protocol.",{"count":139,"type":19},100,[54],"Gastrointestinal stromal tumors (GISTs) are mostly driven by c-kit or PDGFRA mutations, and commonly occur in the stomach and small intestine. Targeted therapy is the mainstay for advanced metastatic GISTs, but there is a lack of effective regimens after drug resistance. Immune checkpoint inhibitors (ICIs) have limited efficacy as monotherapy, while tyrosine kinase inhibitor (TKI) drugs such as regorafenib can improve the immune microenvironment and exert a synergistic effect when combined with ICIs, with more significant efficacy especially in cases with kit exon 17 mutations. This study aims to explore the effectiveness of regorafenib combined with envafolimab in metastatic gastrointestinal stromal tumors with kit exon 17 mutations that have failed standard treatment.",[25,143],"KIT Gene Mutation",[145,146,147],"Gastrointestinal Stromal Tumor","Treatment","kit gene","2026-04-27",{"date":150,"type":32},"2026-04-30",{"date":152,"type":32},"2025-07-14",{"date":154,"type":19},"2027-06-01",{"name":156,"class":39},"Jian Li",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":165,"targetDuration":167,"studyType":21,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":176,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":40},"100613934","a-comprehensive-multinational-gist-registry-100613934","NCT07273045","A Comprehensive, Multinational GIST Registry","reGISTry - a Comprehensive, Multinational GIST Registry","reGISTTry","Inclusion Criteria:\n\n* Diagnosis of a gastrointestinal stromal tumor (GIST)\n* Verbal and written informed consent for participation in the study with planned prospective data collection\n* Physical and mental ability to provide informed consent\n\nExclusion Criteria:\n\n* Severe neurological or psychological illness that impairs the ability to give informed consent",{"count":166,"type":19},1000,"20 Years","Patients diagnosed with a gastrointestinal stromal tumor (GIST), a rare type of tumor in the digestive tractparticipate in this scientific research study, known as a registry study, to help improve understanding and treatment of GIST.\n\nThis study collects medical information and biological samples-such as blood or tumor tissue-from patients. It does not involve new treatments, medications, or medical procedures. The patient's regular medical care will continue as usual, and participation will not require extra appointments or tests.\n\nThe study aims to learn more about how GIST behaves, especially in rare forms such as SDH-deficient or NF1-associated tumors. While targeted drugs are available for many patients, some tumors return or become resistant to treatment. By gathering data from many patients, researchers hope to better understand these challenges, identify risk factors for worse outcomes, and help design future studies and treatments-especially for rare types of GIST.\n\nIf the patient agrees to participate, information will be collected from their medical records, scans (such as CT or MRI), and doctor visits. They may be asked to complete optional questionnaires about their health and quality of life. If they consent, small blood samples (up to 50 ml) may be collected during routine check-ups. If surgery is needed, a small part of the tumor tissue may be stored for research. Other samples-such as saliva, stool, urine, or spinal fluid-may also be collected if they are taken during normal care, to study how bacteria in the body might affect the disease and treatment.\n\nParticipation is completely voluntary. The patient can choose to join or not, and can withdraw at any time without affecting their care or relationship with their doctor. Even if they do not agree to provide biological samples, they can still take part in the study by sharing medical data and scan results.",[170,25],"Gastrointenstinal Stromal Tumor (GIST)",[24,172,173,174,175],"KIT","SDH-Deficiency","NF1","register","NOT_YET_RECRUITING","2025-11-26",{"date":179,"type":32},"2025-12-09",{"date":181,"type":19},"2026-01-01",{"date":183,"type":19},"2056-01-01",{"name":185,"class":39},"Universität Duisburg-Essen",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":52,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":40},"100587283","prospective-evaluation-of-cornerstone-robotics-sentire-surgical-system-in-major-gastrointestinal-and-urologic-surgery-100587283","NCT06926374","Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery","General Inclusion Criteria for All Procedures:\n\n* Body mass index \\\u003C35 kg\u002Fm2\n* Suitable for the listed minimally invasive surgical procedures for treatment of respective diseases\n* Willingness to participate as demonstrated by giving informed consent\n\nGeneral Exclusion Criteria for All Procedures:\n\n* Contraindication to general anesthesia\n* Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention\n* Untreated active infection\n* Noncorrectable coagulopathy\n* Presence of another malignancy or distant metastasis\n* Emergency surgery\n* Vulnerable population (e.g., mentally disabled, pregnancy)\n\nRobotic Colorectal Resection\n\nInclusion Criteria:\n\n\\- Adenocarcinoma or large adenoma (not amenable to endoscopic removal) located at the colorectum (from the cecum to the anal verge) amenable to minimally invasive surgery\n\nExclusion Criteria:\n\n* T4 tumor\n* Recurrent tumor\n* Extensive previous abdominal surgery precluding minimally invasive surgery\n\nRobotic Transanal Total Mesorectal Excision\n\nInclusion Criteria:\n\n\\- Mid\u002Flow rectal adenocarcinoma located \\\u003C12 cm from the anal verge\n\nExclusion Criteria:\n\n* T4 tumor or involvement of circumferential resection margin even after neoadjuvant therapy\n* Tumor requiring multivisceral resection\n* Tumor requiring abdominoperineal resection; recurrent rectal tumor\n* T1 tumor that can be treated by local excision\n* Extensive previous abdominal surgery\n\nRobotic Rectopexy\n\nInclusion Criteria:\n\n* Clinically diagnosed with previously untreated and uncomplicated rectal prolapse or enterocele\n\nExclusion Criteria:\n\n\\- Extensive previous abdominal surgery precluding minimally invasive surgery\n\nRadical Prostatectomy\n\nInclusion Criteria:\n\n\\- Clinically diagnosed with nonmetastatic adenocarcinoma of prostate\n\nExclusion Criteria:\n\n\\- Previous history of prostate surgery (e.g., transurethral resection of prostate)\n\nTotal or Partial Nephrectomy\n\nInclusion Criteria:\n\n\\- Clinically diagnosed with nonmetastatic kidney cancer\n\nExclusion Criteria:\n\n* Previous ipsilateral kidney surgery\n* Complex kidney anatomy (e.g., horseshoe kidney, complex renal vascular anatomy)\n\nRadical Cystectomy\n\nInclusion Criteria:\n\n\\- Clinically diagnosed with nonmetastatic bladder cancer\n\nRobotic Esophageal Hiatal Surgery and Fundoplication\n\nInclusion Criteria:\n\n\\- Clinically diagnosed with Hiatal Hernia and \u002F or Gastroesophageal reflux disease amendable to fundoplication\n\nExclusion Criteria:\n\n\\- Previous history of laparotomy precluding minimally invasive surgery\n\nRobotic Gastrectomy\n\nInclusion Criteria:\n\n\\- Clinical diagnosis of gastric tumor (Adenocarcinoma or Gastrointestinal Stromal Tumor (GIST)) amendable to minimally invasive radical gastrectomy\n\nExclusion Criteria:\n\n\\- Previous history of laparotomy precluding minimally invasive surgery\n\nRobotic Esophagectomy\n\nInclusion Criteria:\n\n\\- Clinical diagnosis of carcinoma of esophagus amendable to minimally invasive esophagectomy\n\nExclusion Criteria:\n\n\\- Esophageal carcinoma after definitive chemoradiotherapy and indicated for salvage esophagectomy\n\nRobotic Cholecystectomy\n\nInclusion Criteria:\n\n\\- Symptomatic gallbladder stones clinically indicated for laparoscopic cholecystectomy\n\nExclusion Criteria:\n\n* Acute cholecystitis\n* Previous history of abdominal surgery","80 Years",{"count":194,"type":19},90,[81],"Robotic assisted surgery has been performed for more than two decades with good success and safety profile. However, there was only one dominating robotic surgical system available in the past which led to high cost for robotic surgery. Recently, a new robotic surgical system (Sentire Robotic Surgical System) was introduced by researchers of The Chinese University of Hong Kong (CUHK). This new robotic surgical system aims to achieve similar outcomes and standards of robotic surgery performed using the dominating system but with a significantly lower cost. The technologic innovation and development of this new robotic system is made by the Cornerstone Robotics Limited, which is based in Hong Kong. In a pilot clinical study conducted at Prince of Wales Hospital involving 55 patients, the Sentire Robotic Surgical System had demonstrated high success rate with minimal complications in patients who underwent robotic colorectal, upper gastrointestinal, and urologic surgery. Researchers of CUHK would therefore like to conduct another prospective study to further evaluate the efficacy and safety of Sentire Surgical System C1000 in major gastrointestinal and urologic surgery with expanded indications. It is believed that the results of this study will provide data to support its use for wide range of procedures with minimal access trauma, for the benefit of patients. This system will also lead to a wider range of clinical application for minimally invasive surgery with a cost-effective model.",[198,199,200,201,202,203,25,204,205,206],"Colorectal Carcinoma","Rectal Prolapse","Prostate Cancer (Adenocarcinoma)","Bladder Cancer","Kidney Cancer","Hiatal Hernia With Gastroesophageal Reflux Disease","Esophageal Cancer","Gallstones","Gastric Cancer","2025-04-11",{"date":209,"type":32},"2025-04-16",{"date":211,"type":32},"2025-03-25",{"date":213,"type":19},"2027-04",{"name":215,"class":39},"Chinese University of Hong Kong"]